EDUCATION

Psilocybin:

Depression

1. Robin Carhart-Harris, Ph.D., Bruna Giribaldi, et al. Trial of Psilocybin versus Escitalopram for Depression. April 15, 2021, N Engl J Med 2021; 384:1402-1411  
2. Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021 May 1;78(5):481-489. 
3. Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry. 2016 Jul 1;3(7):619-27.
4. Carhart-Harris RL, Bolstridge M, Day CM, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 2018 Feb;235(2):399-408.
5. Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of psychopharmacology. 2016 Dec;30(12):1181-97.
6. Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of psychopharmacology. 2016 Dec;30(12):1165-80.
7. https://nyulangone.org/news/single-dose-hallucinogenic-drug-psilocybin-relieves-anxiety-depression-patients-advanced-cancer
8. Griffiths RR. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of psychopharmacology (Oxford). 12/2016;30(12):1181-1197. doi: 10.1177/0269881116675513.
9. Ross S. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of psychopharmacology (Oxford). 12/2016;30(12):1165-1180. doi: 10.1177/0269881116675512.
10. Agin-Liebes GI. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of psychopharmacology (Oxford). 02/2020;34(2):155-166. doi: 10.1177/0269881119897615.

 

PTSD

1. https://med.nyu.edu/departments-institutes/population-health/divisions-sections-centers/medical-ethics/education/high-school-bioethics-project/learning-scenarios/ptsd-treatment-psychedelics#:~:text=In%20the%20study%2C%20mice%20that,occurs%20in%20patients%20with%20PTSD.
2. https://www.nature.com/articles/d41586-021-00187-9
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311646/
4. Catlow BJ, Song S, Paredes DA, Kirstein CL, Sanchez-Ramos J (2013) Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res 228:481–491.

https://link.springer.com/article/10.1007%252Fs00221-013-3579-0

1. Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, Greer GR (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68:71.

https://jamanetwork.com/journals/jamapsychiatry/article-abstract/210962

Others

Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol (Oxf) 29:289–299.

Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry. 2006 Nov 11;67(11):1735-40.

Garcia-Romeu A, R Griffiths R, W Johnson M. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current drug abuse reviews. 2014 Dec 1;7(3):157-64.

Erritzoe D, Roseman L, Nour MM, MacLean K, Kaelen M, Nutt DJ, Carhart‐Harris RL. Effects of psilocybin therapy on personality structure. Acta Psychiatrica Scandinavica. 2018 Nov;138(5):368-78.

Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. The American journal of drug and alcohol abuse. 2017 Jan 2;43(1):55-60.

 

MDMA

PTSD

1. Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J, et al. 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress
2. disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. (2018) 5:486–97
3. Mithoefer MC, Wagner TM, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. (2010) 25:439–52. doi: 10.1177/0269881110378371
4. Sessa B, Higbed L, Nutt D. A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy. Front Psychiatry. 2019 Mar 20;10:138. doi: 10.3389/fpsyt.2019.00138. PMID: 30949077; PMCID: PMC6435835.
5. https://maps.org/wp-content/uploads/2013/11/MDMAIB12thEditionFinal17AUG2020.pdf

 

Ketamine

Depression

1. Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial, Michael F. Grunebaum, Hanga C. Galfalvy, Tse-Hwei Choo, John G. Keilp, Vivek K. Moitra, Michelle S. Parris, Julia E. Marver, Ainsley K. Burke, Matthew S. Milak, M. Elizabeth Sublette, Maria A. Oquendo, and J. John Mann, American Journal of Psychiatry 2018 175:4, 327-335
2. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial, Jennifer B. Dwyer, Angeli Landeros-Weisenberger, Jessica A. Johnson, Amalia Londono Tobon, José M. Flores, Madeeha Nasir, Kevin Couloures, Gerard Sanacora, and Michael H. Bloch, American Journal of Psychiatry 2021 178:4, 352-362
3. Papakostas GI, Salloum NC, Hock RS, et al: Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis. J Clin Psychiatry 2020; 81:19r12889
4. Ochs-Ross R, Daly EJ, Zhang Y, et al: Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression: TRANSFORM-3. Am J Geriatr Psychiatry 2020; 28:121–141
5. Bahji A, Vazquez GH, Zarate CA: Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord 2021; 278:542–555
6. Wei Zheng, Yan-Ling Zhou, et al, Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression, Journal of Psychiatric Research, Volume 106, 2018, Pages 61-68,

IM Ketamine: 

1. Dames S, Kryskow P, Watler C. A Cohort-Based Case Report: The Impact of Ketamine-Assisted Therapy Embedded in a Community of Practice Framework for Healthcare Providers With PTSD and Depression. Front Psychiatry. 2022 Jan 12;12:803279. doi: 10.3389/fpsyt.2021.803279. PMID: 35095617; PMCID: PMC8790057.
2. Chilukuri, H, Reddy, N, Pathapati, R, Manu, A, Jollu, S, Shaik, A. Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian J Psychol Med 2014; 36(1): 71–6.
3. 1. Harihar C, Dasari P, Srinivas JS. Intramuscular ketamine in acute depression: A report on two cases. Indian J Psychiatry. 2013;55(2):186-188. doi:10.4103/0019-5545.111461
   2. Green, S. M., Rothrock, S. G., Lynch, E. L., Ho, M., Harris, T., Hestdalen, R., … & Westcott, K. (1998). Intramuscular ketamine for pediatric sedation in the emergency department: safety profile in 1,022 cases. Annals of emergency medicine, 31(6), 688-697.
   3. Cusin, C., Hilton, G. Q., Nierenberg, A. A., & Fava, M. (2012). Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. American Journal of Psychiatry, 169(8), 868-869.

   Andrade, C. (2017). Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency?. The Journal of clinical psychiatry, 78(7), 10106.